Johnson & Johnson’s coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.
More than 90 percent of the study’s 805 participants had neutralizing antibodies offering protection against COVID-19 29 days after receiving a single dose of the vaccine, the New Jersey-based drugmaker said Wednesday.
The antibodies stuck around for at least 71 days among the participants ranging in age from…
Click here to view the original article.
